We would like to correct an article which appeared in the December 2007 issue of Pharmaceutical Marketing referring to the suspension of the arthritis drug Prexige (lumiracoxib).
In this article, we referred to this being a Bayer product; this is not the case. We would like to apologise to Bayer for our mistake and have corrected the story online.
The corrected story can be found here
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...